Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept vs sulphasalazine in ankylosing spondylitis
2005-001549-41Phase 3Completed
- Sponsor
- Wyeth
- Start
- Oct 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etanercept in ankylosing spondylitis (AS) (2 arms), sponsored by Wyeth. Primary endpoint: ASAS 20 response at Week 16. Started Oct 2005; status: completed.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2005-001549-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001549-41.